Key Takeaways
- Ketamine is an FDA-approved dissociative anesthetic with a well-established safety profile in medical settings; esketamine (Spravato) is FDA-approved for treatment-resistant depression and depression with suicidal ideation.
- Evidence for ketamine specifically in addiction treatment is preliminary, with promising early signals for alcohol and cocaine use disorder but no Phase 3 trial data yet available.
- Ketamine has its own addiction potential, and ketamine use disorder is a recognized clinical condition that can cause severe urological and liver damage with chronic use.
- The commercial ketamine clinic industry varies widely in clinical rigor; patients should carefully evaluate the credentials of providers and the comprehensiveness of care offered.
- Ketamine may be most useful as an adjunct to comprehensive addiction treatment rather than as a standalone intervention, particularly for patients with co-occurring treatment-resistant depression.
- Trust SoCal in Orange County offers comprehensive evidence-based addiction treatment; contact us at (949) 280-8360 to discuss all available treatment options.
Introduction: Ketamine's Complicated Relationship with Addiction Medicine
Ketamine occupies a uniquely paradoxical position in addiction medicine: it is simultaneously a substance with documented addiction potential and an investigational therapeutic agent for treating addiction. First synthesized in 1962 and approved by the FDA as a dissociative anesthetic in 1970, ketamine has been used safely in medical settings for decades. Its rapid-onset antidepressant effects, discovered somewhat serendipitously in the 1990s, sparked intense scientific interest in its potential for treating mood disorders and, more recently, substance use disorders. The 2019 FDA approval of esketamine nasal spray (Spravato) for treatment-resistant depression marked a watershed moment, establishing the first new class of antidepressant approved in decades and legitimizing the therapeutic use of ketamine derivatives.
The ketamine clinic industry has grown explosively in the years since esketamine's approval, with hundreds of clinics opening across the United States, including many in Southern California. These clinics range from highly credentialed medical practices offering evidence-based protocols with comprehensive psychiatric and psychological support to commercial operations with minimal clinical oversight focused primarily on volume and profit. This variability in quality makes it essential for patients and families to approach ketamine clinics with informed skepticism, asking rigorous questions about the scientific basis for claims, the credentials of providers, and the comprehensiveness of care offered.
This review aims to provide an honest assessment of what the scientific literature currently supports regarding ketamine for addiction, where the evidence is promising but incomplete, what the risks are, and how ketamine might appropriately fit into a comprehensive addiction treatment strategy. At Trust SoCal in Orange County, our clinical team evaluates emerging evidence with the same rigorous standards we apply to all treatment decisions, ensuring that our patients receive care that is genuinely evidence-based rather than simply evidence-adjacent. Call us at (949) 280-8360 with any questions.
The Neuroscience of Ketamine: NMDA Antagonism and Rapid Antidepressant Effects
Ketamine's primary mechanism of action is antagonism of the N-methyl-D-aspartate (NMDA) glutamate receptor, which distinguishes it fundamentally from conventional antidepressants that act on monoamine systems. By blocking NMDA receptors, ketamine triggers a cascade of downstream effects including increased release of brain-derived neurotrophic factor (BDNF), activation of the mTOR signaling pathway, and rapid synaptogenesis in the prefrontal cortex. These effects produce antidepressant responses within hours rather than the weeks required by conventional antidepressants, and have been documented in patients who failed to respond to multiple adequate trials of standard treatments.
For addiction specifically, the NMDA antagonism mechanism is theoretically relevant to several aspects of the disorder. Glutamate plays a central role in the synaptic plasticity mechanisms that underlie drug-associated learning and the formation of craving memories. NMDA receptor antagonism may disrupt the reconsolidation of drug-associated memories when administered shortly after their retrieval, potentially weakening the motivational impact of environmental cues that trigger craving. Additionally, ketamine's rapid antidepressant effect may address the anhedonia and dysphoria that characterize protracted withdrawal and frequently drive relapse, particularly in early recovery from alcohol and stimulant use disorders.
The dissociative effects of ketamine, which produce experiences of ego dissolution, altered perception of space and time, and a sense of detachment from habitual mental patterns, may also have therapeutic relevance analogous to the effects observed with classical psychedelics like psilocybin. Some researchers hypothesize that ketamine's dissociative effects, rather than simply being side effects to be minimized, may be therapeutically active components that facilitate psychological transformation. This perspective has led to the development of ketamine-assisted psychotherapy protocols that deliberately leverage the dissociative state for therapeutic processing, similar in concept to psilocybin-assisted therapy models.
Esketamine (Spravato) is FDA-approved only for treatment-resistant depression and major depressive disorder with suicidal ideation, not for addiction. IV ketamine infusions are not FDA-approved for any psychiatric indication, though they are legally used off-label. Claims of FDA approval for addiction treatment are inaccurate.
Forms of Ketamine Used in Clinical Settings
Several formulations and routes of administration are used in both approved and investigational ketamine treatments, each with different pharmacokinetic profiles and evidence bases.
- IV Ketamine Infusion: Racemic ketamine administered intravenously; not FDA-approved for depression or addiction but widely used off-label; most studied formulation in research settings; requires medical monitoring.
- Esketamine Nasal Spray (Spravato): FDA-approved for treatment-resistant depression and major depression with suicidal ideation; must be administered in a certified healthcare setting with two-hour post-dose monitoring; covered by many insurance plans for approved indications.
- Intramuscular Ketamine: Used in some clinical settings; less precise dosing than IV; faster onset than oral formulations; used in some addiction-specific research protocols.
- Oral/Sublingual Ketamine: Lowest bioavailability; used primarily for at-home maintenance between in-office infusion sessions; not approved for any indication but prescribed off-label at some clinics.
What the Research Actually Shows: Ketamine for Addiction
The evidence base for ketamine in addiction treatment is genuinely promising but remains in early phases, concentrated primarily in Phase 1 and Phase 2 trials with relatively small sample sizes. The most robust evidence comes from research on alcohol use disorder. A 2022 randomized controlled trial published in the American Journal of Psychiatry by Krupitsky and colleagues in Russia found that three ketamine infusions combined with motivational enhancement therapy significantly reduced relapse rates in alcohol use disorder compared to diazepam infusions plus therapy. Approximately 66 percent of the ketamine group maintained abstinence at one year compared to 24 percent of controls, an effect size that substantially exceeds current pharmacological treatments for alcohol use disorder.
Research on ketamine for cocaine use disorder has produced mixed results. Several small studies have found that single ketamine infusions administered immediately before cue exposure sessions reduced craving responses to cocaine-associated stimuli, consistent with the memory reconsolidation hypothesis. A 2021 pilot trial at Columbia University found that repeated ketamine infusions combined with mindfulness-based relapse prevention reduced cocaine use in participants with cocaine use disorder, though the sample size was small and control conditions limited. These findings warrant larger trials but do not yet support clinical recommendation of ketamine for cocaine addiction.
For opioid use disorder, ketamine research is complicated by the fact that many individuals in this population have extensive experience with dissociative drugs and may be at elevated risk for ketamine misuse. A small number of case series and pilot studies have explored ketamine as an adjunct to buprenorphine treatment, with generally positive results on mood and craving outcomes, but rigorous controlled trials are lacking. The risk-benefit calculus for ketamine in opioid use disorder requires careful individual assessment and would generally only be appropriate in the context of co-occurring treatment-resistant depression.
Ketamine has documented addiction potential. Ketamine use disorder is characterized by compulsive use despite severe physical consequences including ketamine-induced uropathy, a devastating bladder condition requiring surgery in severe cases, and ketamine cholangiopathy affecting the liver and bile ducts. Any therapeutic use must be carefully supervised.
Evaluating Ketamine Clinics: What Questions to Ask
The proliferation of ketamine clinics in Southern California has created significant variability in the quality and appropriateness of care offered. Well-operated ketamine clinics are staffed by board-certified anesthesiologists or psychiatrists with specific training in ketamine-assisted therapy, conduct thorough pre-treatment psychiatric and medical evaluations, provide structured preparation and integration support, monitor patients carefully during and after infusions, and maintain close communication with primary addiction treatment providers. At the other end of the spectrum, some commercial clinics offer minimal clinical oversight, inadequate screening for contraindications, and no integration therapy, functioning essentially as pharmacological delivery services.
Before engaging with any ketamine clinic, patients and families should ask specific, direct questions: What are the credentials of the administering physician? What pre-treatment screening is conducted, and what conditions are considered contraindications? Is integration therapy included, and if so, what is the training of the therapist? How does the clinic monitor for signs of ketamine misuse or dependence? How does the clinic coordinate with a patient's existing addiction treatment providers? What outcome data does the clinic collect and track? How many sessions are recommended and on what basis? Clinics that answer these questions vaguely or that cannot provide evidence-based rationale for their protocols should be approached with caution.
For individuals in addiction recovery specifically, the decision to pursue ketamine therapy requires careful consideration in collaboration with existing treatment providers. Introducing a dissociative substance with addiction potential into an addiction treatment plan carries inherent risks that must be weighed against potential benefits. Patients should be honest with potential ketamine providers about their substance use history, as this information is essential for appropriate risk assessment. Trust SoCal's clinical team can help patients evaluate whether ketamine therapy might be appropriate as an adjunct to their treatment plan and can assist with referrals to reputable providers when indicated. Contact us at (949) 280-8360 for guidance.
Red Flags When Evaluating Ketamine Clinics
Certain characteristics of ketamine clinics should prompt caution or avoidance, as they suggest inadequate clinical standards.
- Claims of FDA approval for addiction treatment: Ketamine is not FDA-approved for addiction; esketamine is approved only for treatment-resistant depression and depression with suicidal ideation.
- No pre-treatment psychiatric evaluation: Thorough mental health screening is essential to identify contraindications including active psychosis, poorly controlled bipolar disorder, and active ketamine misuse.
- Minimal integration support: Without psychological integration support, ketamine infusions are unlikely to produce durable therapeutic benefit for addiction.
- At-home administration without supervision: Oral ketamine prescribed for unsupervised home use eliminates the safety monitoring that makes in-office administration appropriate.
- Guarantees of outcomes: No addiction treatment can guarantee outcomes; clinics making specific recovery guarantees are misrepresenting the science.
Ketamine Use Disorder: A Real Risk
A critical consideration in any discussion of ketamine for addiction treatment is the substance's own addiction potential. Ketamine use disorder is a recognized clinical condition in the DSM-5, characterized by escalating use, tolerance, compulsive use despite adverse consequences, and withdrawal. Unlike many other substances, chronic ketamine misuse produces severe and distinctive physical complications. Ketamine-induced uropathy is a condition in which chronic ketamine exposure causes inflammation, fibrosis, and severe contraction of the bladder, producing symptoms including urinary frequency, urgency, pain, and incontinence. In advanced cases, bilateral hydroureteronephrosis and renal failure can occur, requiring cystectomy and urinary diversion surgery.
Ketamine cholangiopathy is an equally serious complication involving inflammation and stricturing of the bile ducts, which can lead to cholestasis, hepatitis, and liver failure. These physical complications are directly related to dose and duration of use, which means that the controlled, limited-dose protocols used in clinical research settings carry substantially lower risk than recreational or compulsive use patterns. Nevertheless, any introduction of ketamine into an addiction treatment context must be accompanied by monitoring for signs of escalating use and must include clear protocols for discontinuation if concerning patterns emerge.
The risk of ketamine misuse is not uniform across all patients in addiction treatment. Individuals with histories of stimulant use disorder may be at elevated risk due to the similar reinforcing properties of these substances. Patients with histories of dissociative drug use, including PCP or DXM, may have pre-existing conditioned responses to dissociative states that increase vulnerability. Any ketamine treatment protocol used in an addiction context should include systematic monitoring for these risk factors and should involve close collaboration between the ketamine provider and the patient's primary addiction treatment team. At Trust SoCal, we evaluate all treatment options with this comprehensive perspective, prioritizing long-term safety and recovery.
Ketamine's therapeutic potential is real, but so is its abuse liability. In addiction medicine, we must hold both truths simultaneously and design protocols that maximize benefit while vigilantly monitoring for harm.
— Addiction Psychiatry perspective on ketamine in clinical practice
Integrating Ketamine Research into Comprehensive Addiction Care
The appropriate role of ketamine in addiction treatment, based on the current evidence, is as a carefully selected adjunct to comprehensive addiction treatment for specific patient populations rather than as a primary or standalone intervention. Patients most likely to benefit from ketamine as part of an addiction treatment plan are those with co-occurring treatment-resistant depression or PTSD that is driving substance use, those who have not responded to multiple adequate trials of standard treatments, and those who have access to high-quality ketamine providers who maintain close coordination with their primary addiction treatment team. For these patients, addressing the co-occurring psychiatric condition with ketamine may create a window of improved mood and psychological flexibility that enhances engagement with core addiction treatment.
Comprehensive addiction treatment at Trust SoCal in Fountain Valley, Orange County, addresses all the dimensions of substance use disorders through evidence-based, multidisciplinary care. Our programs integrate medical treatment, individual and group psychotherapy, family involvement, peer support, and aftercare planning in ways that create synergistic effects greater than any single modality could achieve. We remain current with emerging research including ketamine and psychedelic therapy, and our clinical team can engage patients in informed, nuanced conversations about where these treatments fit and what the realistic expectations should be.
If you or a loved one is struggling with addiction and interested in how emerging treatments might fit into a comprehensive recovery plan, we encourage you to reach out to our team. We are located at 16537 Elm Cir, Fountain Valley, CA 92708, and serve the greater Orange County community. Our admissions team is available around the clock at (949) 280-8360. Evidence-based treatment works, and the landscape of what is available continues to evolve. Trust SoCal is committed to bringing the best of current and emerging science to every patient we serve.
Rachel Handa, Clinical Director
Clinical Director & Therapist